Switch Therapeutics

Switch Therapeutics is an emerging, private biotech company developing next-generation RNAi therapies with its innovative CASi platform, which enables cell-selective and conditionally activated gene silencing. The company has raised a $52 million Series A financing round and is building a pipeline focused on CNS disorders. Its leadership combines scientific expertise from Caltech and Harvard with seasoned biotech operational and financial experience, positioning it to tackle complex neurological diseases with a potentially safer and more targeted therapeutic approach.

Proprietary Conditionally Activated siRNA (CASi) platform, a modular RNAi construct with a biomarker-sensitive sensor domain and an siRNA payload domain designed for cell-type specific gene silencing and self-delivery.

Switch competes with established RNAi leaders like Alnylam and newer biotechs developing advanced oligonucleotide delivery technologies for the CNS (e.g., using GalNAc conjugates, lipid nanoparticles, or other targeting moieties). Its key differentiator is the conditional activation mechanism designed for intrinsic cell-type selectivity.